HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LVMH

This article was originally published in The Rose Sheet

Executive Summary

Sephora opened 24 stores in the U.S. in 2005 and will "continue to expand vigorously" in established markets as well as high-potential markets such as Central Europe in 2006, LVMH says in annual report released March 2. Profit from recurring operations for Selective Retailing advanced 46% to $417.2 mil. (€1=$1.20) in 2005. In Perfumes and Cosmetics, profit from recurring operations increased 15% to $208 mil., due to major French brands gaining market share and smaller companies maintaining "rapid rate" of growth, according to company. In 2006, Parfums Christian Dior will launch "major skin care and makeup," Guerlain will introduce Orchidée Impériale skin care as well as expand KissKiss, and Parfums Kenzo will launch a new women's scent in the second half, firm notes. Profit from recurring operations for LVMH grew 16% to $3.3 bil...

You may also be interested in...



House Of Representatives Concerned Over Complex Generics

The Committee on Energy and Commerce of the US House of Representatives has requested a set of documents from the FDA in order to assess whether the agency is doing enough to address the challenge of approving complex generics within its existing authorities, or whether additional authority is needed.

Stockwatch: Earnings Season Catches An Early Cold As Coronavirus Sweeps In

As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.

 

 

Pipeline Watch: Phase III Readouts For Surufatinib, Tislelizumab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

UsernamePublicRestriction

Register

RS013760

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel